Related Experiment Video

Updated: Feb 7, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.4K

BRAF/MEK Combo Approved for Melanoma

    Cancer Discovery
    |July 19, 2018
    PubMed

    Insights

    The FDA approved encorafenib/binimetinib for BRAF-mutant melanoma. This combination therapy significantly improved progression-free survival compared to vemurafenib alone in a Phase III trial.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • The U.S. Food and Drug Administration (FDA) has approved the combination therapy of encorafenib and binimetinib for patients diagnosed with metastatic or inoperable melanoma.
    • This approval specifically targets patients harboring the BRAF V600E or V600K mutation, a common genetic driver in melanoma.

    Discussion:

    • The FDA's decision was informed by pivotal Phase III clinical trial data.
    • The trial demonstrated a substantial improvement in median progression-free survival for patients receiving the encorafenib/binimetinib combination.

    Key Insights:

    • Median progression-free survival was 14.9 months for the combination arm.
    • The control group, treated with vemurafenib monotherapy, achieved a median progression-free survival of 7.3 months.
    • This represents a doubling of progression-free survival, highlighting the efficacy of the combination therapy.

    Outlook:

    • This approval offers a new, more effective treatment option for patients with BRAF-mutant melanoma.
    • Further research may explore long-term survival benefits and potential resistance mechanisms.

    More Related Videos

    A Melanoma Patient-Derived Xenograft Model07:07

    A Melanoma Patient-Derived Xenograft Model

    Published on: May 20, 2019

    13.2K
    Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model10:23

    Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

    Published on: November 13, 2012

    14.2K

    Related Concept Videos

    FDA Approved Drugs: Changes to Approved Drugs01:26

    FDA Approved Drugs: Changes to Approved Drugs

    Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
    273
    Obedience01:08

    Obedience

    According to obedience research, we may harm others under the forceful pressures of an authority figure (Milgram, 1974). How about if the inappropriate orders were delivered with less force? The increasing interdependence between nurses and physicians compelled Hofling and his colleagues to explore nurses’ reactions to a potentially harmful medical request made by the perceived authority figure, the doctor (Hofling, Brotzman, Dalrymple, Graves, & Pierce, 1966). In this situation,...
    35.7K
    Ethics in Research01:56

    Ethics in Research

    Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
    25.8K